Angiogenex Co-Developing Anti-Cancer Drug With World Renowned Cancer Center
Digital Journal,
AngioGenex, Inc. Announces an Exclusive Agreement With Memorial Sloan Kettering Cancer Center.
A Small-Molecule Pan-Id Antagonist Inhibits Pathologic Ocular Neovascularization
Overview of attention for article published in Cell Reports, October 2019
Altmetric Badge
About this Attention Score
-
In the top 25% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (92nd percentile)
-
Good Attention Score compared to outputs of the same age and source (69th percentile)
Readers on
- mendeley
- 63 Mendeley
